[go: up one dir, main page]

MA38686A1 - Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés - Google Patents

Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés

Info

Publication number
MA38686A1
MA38686A1 MA38686A MA38686A MA38686A1 MA 38686 A1 MA38686 A1 MA 38686A1 MA 38686 A MA38686 A MA 38686A MA 38686 A MA38686 A MA 38686A MA 38686 A1 MA38686 A1 MA 38686A1
Authority
MA
Morocco
Prior art keywords
cell wall
teichoic acid
acid antibodies
conjugates
associated conjugates
Prior art date
Application number
MA38686A
Other languages
English (en)
Inventor
Richard Vandlen
Eric Brown
Martine Darwish
John Flygare
Wouter Hazenbos
Byoung-Chul Lee
Sophie M Lehar
Sanjeev Mariathasan
John Hiroshi Morisaki
Thomas H Pillow
Leanna Staben
Klaus Koefoed
Magnus Strandh
Peter S Andersen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/039113 external-priority patent/WO2014193722A1/fr
Priority claimed from US14/284,609 external-priority patent/US20140356375A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA38686A1 publication Critical patent/MA38686A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des anticorps anti-acide téichoïque de la paroi cellulaire et leurs conjugués antibiotiques, ainsi que leurs méthodes d'utilisation.
MA38686A 2013-05-31 2014-05-30 Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés MA38686A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361829466P 2013-05-31 2013-05-31
US201361829461P 2013-05-31 2013-05-31
PCT/US2014/039113 WO2014193722A1 (fr) 2013-05-31 2014-05-22 Anticorps anti-acides téichoïques de paroi et leurs conjugués
US14/284,609 US20140356375A1 (en) 2013-05-31 2014-05-22 Anti-wall teichoic antibodies and conjugates
PCT/US2014/040324 WO2014194247A1 (fr) 2013-05-31 2014-05-30 Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés

Publications (1)

Publication Number Publication Date
MA38686A1 true MA38686A1 (fr) 2017-10-31

Family

ID=51989438

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38686A MA38686A1 (fr) 2013-05-31 2014-05-30 Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés

Country Status (30)

Country Link
EP (2) EP3004162B1 (fr)
JP (2) JP6469094B2 (fr)
KR (1) KR20160015227A (fr)
CN (2) CN112430266A (fr)
AU (2) AU2014273939B2 (fr)
BR (1) BR112015029838A2 (fr)
CA (1) CA2910029A1 (fr)
CL (1) CL2015003496A1 (fr)
CR (1) CR20150626A (fr)
DK (1) DK3004162T3 (fr)
EA (1) EA201592078A1 (fr)
ES (1) ES2793174T3 (fr)
HK (1) HK1220982A1 (fr)
HR (1) HRP20200812T1 (fr)
HU (1) HUE050451T2 (fr)
IL (1) IL242175B (fr)
LT (1) LT3004162T (fr)
MA (1) MA38686A1 (fr)
MX (2) MX369022B (fr)
MY (1) MY177774A (fr)
PE (1) PE20160715A1 (fr)
PH (1) PH12015502636A1 (fr)
PL (1) PL3004162T3 (fr)
PT (1) PT3004162T (fr)
RS (1) RS60256B1 (fr)
SG (1) SG11201509839TA (fr)
SI (1) SI3004162T1 (fr)
UA (1) UA120088C2 (fr)
WO (1) WO2014194247A1 (fr)
ZA (1) ZA201507977B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913011A1 (fr) 2013-05-31 2014-12-04 Genentech, Inc. Anticorps anti-acides teichoiques de paroi et leurs conjugues
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
CN105848685B (zh) 2013-12-16 2020-09-22 健泰科生物技术公司 拟肽化合物及其抗体药物偶联物
SI3900742T1 (sl) 2014-09-11 2024-10-30 Seagen Inc. Ciljana dostava zdravilnih snovi, ki vsebujejo terciarne amine
MX2017007231A (es) 2014-12-03 2017-11-08 Genentech Inc Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
EP3226909A1 (fr) * 2014-12-03 2017-10-11 Genentech, Inc. Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
EP3226911A1 (fr) 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Conjugués d'anticorps anti staphylocoque doré et de rifamycine et utilisations de ceux-ci
TW201709934A (zh) 2015-06-15 2017-03-16 建南德克公司 抗體及免疫結合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CA3006000A1 (fr) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugues de composes de tubulysine quaternises
US10336683B2 (en) * 2016-03-04 2019-07-02 Genentech, Inc. Process for the preparation of an antibody-rifamycin conjugate
US20200123237A1 (en) * 2016-05-18 2020-04-23 Genmab B.V. Antibodies and methods of use thereof in treatment of infectious disease
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
SG11202001543XA (en) 2017-09-08 2020-03-30 Seattle Genetics Inc Process for the preparation of tubulysins and intermediates thereof
EP3829648A1 (fr) 2018-07-27 2021-06-09 Promega Corporation Conjugués contenant de la quinone
WO2021195716A1 (fr) * 2020-04-02 2021-10-07 Monash University Conjugués antibiotiques
GB202214756D0 (en) * 2022-10-07 2022-11-23 Univ Oxford Innovation Ltd Product

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB877732A (en) 1958-08-12 1961-09-20 Lepetit Spa The antibiotic rifomycin, its components and methods of preparing same
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4610919A (en) 1985-06-14 1986-09-09 Fiber Bond Corporation Binder for fibrous padding
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP2544375B2 (ja) 1986-07-14 1996-10-16 鐘淵化学工業株式会社 アルキル置換ベンゾキサジノリフアマイシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1304363C (fr) 1988-11-01 1992-06-30 Takehiko Yamane Derive 3-hydroxybenzoxazinorifamycine, procede pour sa preparation et agent antibacterien en contenant
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5545721A (en) 1992-12-21 1996-08-13 Ophidian Pharmaceuticals, Inc. Conjugates for the prevention and treatment of sepsis
US6660267B1 (en) 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5981522A (en) 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
JP3963976B2 (ja) 1995-12-08 2007-08-22 株式会社カネカ クラミジア感染症治療剤
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
ES2418360T3 (es) 1999-04-09 2013-08-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
JP2003503015A (ja) 1999-05-03 2003-01-28 メダレツクス・インコーポレーテツド スタフィロコッカス・アウレウスに対するヒト抗体
CA2388245C (fr) 1999-10-19 2012-01-10 Tatsuya Ogawa L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
BR0114475A (pt) 2000-10-06 2003-12-23 Kyowa Hakko Kogyo Kk Célula para a produção de composição de anticorpo
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (fr) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-aminobenzyl ether dans des agents d'administration de medicaments
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
EP1482972A4 (fr) 2001-11-20 2005-11-23 Seattle Genetics Inc Traitement des troubles immunologiques au moyen des anticorps anti-cd30
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
CA2481837A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
AU2003294210A1 (en) 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2502413A1 (fr) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Analyse quantitative d'isoformes de proteines utilisant la spectrometrie de masse a temps de vol par desorption/ionisation laser assistee par matrice
US20040247605A1 (en) * 2002-12-02 2004-12-09 Kokai-Kun John Fitzgerald Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
JP4351674B2 (ja) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体とその使用法およびその使用
KR20070029616A (ko) 2003-08-22 2007-03-14 액티브 바이오틱스 인코포레이티드 리파마이신 유사체 및 그의 용도
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
NZ547633A (en) * 2003-11-06 2010-08-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005062882A2 (fr) 2003-12-23 2005-07-14 Activbiotics, Inc Analogues de rifamycine et leurs utilisations
CA2556752C (fr) 2004-02-23 2016-02-02 Genentech, Inc. Liants et conjugues heterocycliques auto-immolateurs
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
EP1917020B1 (fr) 2005-07-07 2016-05-25 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
KR101327635B1 (ko) * 2005-08-11 2013-11-12 타간타 테라퓨틱스 인크. 포스폰산화 리파마이신, 및 그의 뼈 및 관절 감염의 저지및 치료 용도
AU2006326456A1 (en) 2005-12-14 2007-06-21 Activbiotics Pharma Llc Rifamycin analogs and uses thereof
AU2008221119B2 (en) 2007-03-01 2013-11-14 Les Laboratoires Servier Method for cloning cognate antibodies
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
KR101622412B1 (ko) 2007-10-19 2016-05-18 제넨테크, 인크. 시스테인 조작된 항-ｔｅｎｂ２ 항체 및 항체 약물 접합체
WO2009140236A2 (fr) 2008-05-12 2009-11-19 Strox Biopharmaceuticals, Llc Préparations d'anticorps spécifiques de staphylococcus aureus
US8524691B2 (en) 2008-08-13 2013-09-03 The Medicines Company Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
BRPI0920041A2 (pt) 2008-10-06 2017-06-27 Univ Chicago composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas
EA031447B1 (ru) * 2009-07-15 2019-01-31 Аимм Терапьютикс Б.В. Антитела, которые связываются с sdr белками, и способы их использования
RU2755066C2 (ru) 2010-06-08 2021-09-13 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
DK2678037T3 (en) 2011-02-25 2015-03-09 Lonza Ag Branched linker for protein pharmaceutical conjugates
KR20150024315A (ko) * 2012-05-07 2015-03-06 재단법인 목암생명공학연구소 포도상구균 감염 예방용 백신 조성물

Also Published As

Publication number Publication date
IL242175B (en) 2020-02-27
MX2019012708A (es) 2019-12-16
CA2910029A1 (fr) 2014-12-04
CN112430266A (zh) 2021-03-02
CL2015003496A1 (es) 2016-12-23
CN105358573A (zh) 2016-02-24
KR20160015227A (ko) 2016-02-12
JP2016525343A (ja) 2016-08-25
JP6469094B2 (ja) 2019-02-13
SI3004162T1 (sl) 2020-07-31
MX369022B (es) 2019-10-25
EP3004162B1 (fr) 2020-03-11
HRP20200812T1 (hr) 2020-08-07
UA120088C2 (uk) 2019-10-10
EP3004162A1 (fr) 2016-04-13
JP2019054801A (ja) 2019-04-11
ZA201507977B (en) 2017-01-25
HUE050451T2 (hu) 2020-12-28
LT3004162T (lt) 2020-06-10
EA201592078A1 (ru) 2016-04-29
WO2014194247A1 (fr) 2014-12-04
AU2019279986A1 (en) 2020-01-16
HK1220982A1 (zh) 2017-05-19
CN105358573B (zh) 2020-10-30
SG11201509839TA (en) 2016-01-28
PE20160715A1 (es) 2016-08-01
AU2014273939A1 (en) 2015-11-26
MY177774A (en) 2020-09-23
DK3004162T3 (da) 2020-05-18
MX2015016405A (es) 2016-04-11
BR112015029838A2 (pt) 2017-09-26
RS60256B1 (sr) 2020-06-30
EP3381939A1 (fr) 2018-10-03
ES2793174T3 (es) 2020-11-13
PL3004162T3 (pl) 2020-07-27
PT3004162T (pt) 2020-05-27
CR20150626A (es) 2016-01-29
AU2014273939B2 (en) 2019-09-19
PH12015502636A1 (en) 2016-03-07

Similar Documents

Publication Publication Date Title
MA38686A1 (fr) Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
MA44550B1 (fr) Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés
MA40671B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA34881B1 (fr) Anticorps et immunoconjugués anti-mésothéline
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
MA34521B1 (fr) Polypeptides de relaxine modifiés et leurs utilisations
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA38960A1 (fr) Formulations d'anticorps anti-pdl1
MA44637B1 (fr) Composes hétérocycliques et leurs utilisations
MA33551B1 (fr) Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
MA38341A1 (fr) Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
EP2569330A4 (fr) Variants de la chlorotoxine, conjugués, et leurs méthodes d'utilisation
MX2021015825A (es) Formulaciones de anticuerpos estables acuosas.
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
EP2516624A4 (fr) Lignée cellulaire 3m
MY161868A (en) Anti-bv8 antibodies and uses thereof
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
MA39126A3 (fr) Synthèse d'enantiomère de progestérone et d'intermédiaires de celui-ci
MA39411A (fr) Synthèse de l'énantiomère de la progestérone et ses intermédiaires